MOTS-C (20mg)

Mitochondrial-Derived Peptide (Extended Research Protocol Vial)

MOTS-C (20mg) will be supplied in Australia by Aussie Peptides with fast domestic shipping to all states and territories.

MOTS-C is an endogenous mitochondrial-derived peptide (MDP) encoded in the mitochondrial genome — unusual among mammalian peptides, which are typically nuclear-encoded. First characterised in 2015 by researchers at the University of Southern California, MOTS-C has become a central focus of metabolic and longevity research.

Plasma MOTS-C levels decline with age and correlate with insulin resistance, reduced exercise capacity, and metabolic dysfunction in human observational studies. Mechanistically, MOTS-C translocates from mitochondria to nucleus under metabolic stress and activates AMPK.

The 20mg format suits extended research protocols — twice the compound of the 10mg vial, with better value per milligram.

Key Research Areas

• Insulin Sensitivity — Studied for improved glucose uptake and insulin signalling in type 2 diabetes and metabolic syndrome models
• Exercise Adaptation — Studied for endurance and training response in preclinical models
• Metabolic Ageing — Plasma MOTS-C correlates with biological age markers; studied in longevity research
• AMPK Activation — Studied for cellular energy regulation via AMPK-mediated pathways
• Obesity Models — Studied in high-fat diet models for reversal of insulin resistance and improved fat metabolism

Supplied as lyophilized powder at high purity, verified by HPLC and mass spectrometry. 20mg per vial. Fast domestic shipping across Australia, with batch-specific CoA information available in our CoA Library.

⚠ For in-vitro research and laboratory use only. Not for human consumption.